View More Recent Stories
-
Increasing unusual call option volume: EWW CRSR CENX BROS IAU TEM
-
Tempus AI stock downgraded by William Blair after massive rally
-
William Blair Downgrades Tempus AI Inc (TEM) to Market Perform
-
Increasing unusual put option volume: FMC EA HBAN TPX ICE EXE TKO BBAI MTCH TEM
-
Increasing unusual call option volume: DINO BCRX FMC ACB EA VSH TEM GPRO SAN JCI
-
TD Cowen Reinstates Tempus AI Inc (TEM) at Buy
-
Tempus AI (TEM) call put ratio 3.1 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 5.5 calls to 1 put with a focus on July 70 calls into quarter results
-
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways (TEM)
-
Increasing unusual put option volume: EWC EA YOU XLI EDR MLCO BTG HIMX VERU ALK TKO TEM
-
Tempus AI (TEM) call put ratio 3 calls to 1 put with as share price up 39%
-
Increasing unusual put option volume: LW FTAI WMB WEN XP FAST CFG RGTI CLMT IYR TEM
-
Tempus AI (TEM) Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
-
Tempus AI (TEM) Announces the National Launch of FDA-Approved xT CDx Test
-
Tempus AI Inc (TEM) PT Lowered to $52 at Loop Capital
-
Tempus AI (TEM) Announces xH
-
Tempus AI (TEM) Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
Tempus AI (TEM) Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
-
Tempus AI Inc (TEM) PT Raised to $70 at Piper Sandler
-
Stifel Downgrades Tempus AI Inc (TEM) to Hold
-
Tempus AI Inc (TEM) PT Raised to $56 at Needham
-
Tempus AI (TEM) to Acquire Ambry Genetics, Reports Q3
-
Avacta and Tempus (TEM) Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
-
Tempus AI Inc (TEM) PT Raised to $57 at Loop Capital
-
Tempus AI (TEM) Announces Real World Data Collaboration with BioNTech (BNTX)
-
Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
-
Piper Sandler Starts Tempus AI Inc (TEM) at Neutral
-
Tempus AI, Inc (TEM) Reports Q2 Loss of $6.86; offers guidance
-
BofA Securities Starts Tempus AI Inc (TEM) at Buy
-
Wall Street starts Tempus AI coverage after IPO, shares climb
-
Loop Capital Starts Tempus AI Inc (TEM) at Buy
-
William Blair Starts Tempus AI Inc (TEM) at Outperform
-
Needham Starts Tempus AI Inc (TEM) at Buy
-
TD Cowen Starts Tempus AI Inc (TEM) at Buy, 'largest oncology Dx co.'
-
Morgan Stanley Starts Tempus AI Inc (TEM) at Overweight
-
JPMorgan Starts Tempus AI Inc (TEM) at Overweight
-
Stifel Starts Tempus AI Inc (TEM) at Buy
-
Tempus AI (TEM) Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF
-
Tempus AI (TEM) Prices 11.1M Share IPO at $37/sh
-
Tempus AI (TEM) IPO Opens Higher by 8%
-
Tempus AI (TEM) Indicated At $47, IPO Priced At $37

